TLV does not extend Hemlibra's current subsidy


18 June 2019 - Hemlibra has been included in the high-cost protection since autumn 2018 for the treatment of patients whose inhibitor development has not been lifted by repeated ITI treatments. 

The company has come in with a basis for the patient groups within the approved indication that are not included in the high-cost protection.

TLV believes that prophylactic treatment with Hemlibra is not inferior to preventative treatment with factor VIII drugs in patients with severe haemophilia A.

Read TLV article

Michael Wonder

Posted by:

Michael Wonder